Literature DB >> 29187654

[Analysis for the effect of different regimens on ocular myasthenia gravis in children].

Chentao Liu1, Xia Wang2, Lili Xie2, Jing Peng2, Liwen Wu2, Xiangrong Zheng2.   

Abstract

OBJECTIVE: To evaluate the efficacy, recurrent risk factors and transferable ratio of treatments with 3 different regiments on children with systematic myasthenia gravis (MG).

Methods: The data of 104 children with ocular MG from June 2010 to March 2014 were collected from Department of Pediatric Neurology of Xiangya Hospital and they were retrospectively studied. The patients were divided into 3 groups: a methylprednisolone group (n=44), a prednisone group (n=48) and a bromine pyridostigmine group (n=12). Evaluative system from American MG foundation was used to evaluate the efficacy of treatment and the ratio of ocular MG transformed into systematic MG.

Results: The efficacy in the methylprednisolone group was better than that in the prednisone group, and both of them were better than that in the bromine pyridostigmine group (both P<0.05).Methylprednisolone, prednisone combined with bromine pyridostigmine could reach a better long-term efficacy in children with ocular MG. Early treatment with glucocorticoid could reduce clinical relapse.

Conclusion: A treatment with high-dose methylprednisolone pulse can improve early clinical remission in children with ocular MG. However, there is a similar efficacy in the long run of different glucocorticoid therapeutic regiments. A relatively order onset age, infection and thyroid dysfunction are recurrent risk factors in children with ocular MG.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29187654     DOI: 10.11817/j.issn.1672-7347.2017.11.006

Source DB:  PubMed          Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-7347


  1 in total

1.  Clinical characteristics and outcome predictors of a Chinese childhood-onset myasthenia gravis cohort.

Authors:  Lifen Yang; Yulin Tang; Fang He; Ciliu Zhang; Miriam Kessi; Jing Peng; Fei Yin
Journal:  Front Pediatr       Date:  2022-09-29       Impact factor: 3.569

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.